Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
復星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following sets out the "Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
8 January 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, the resubmitted drug registration application of Foritinib Succinate Capsules (project code: SAF-189; registration category of application: class 1 chemical medicine; hereinafter the "**New Drug**") of Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.* (復星萬邦(江蘇)醫藥集團有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the "**Company**"), was accepted by the National Medical Products Administration recently. The indication under this application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

II. General Information and Major Research Progress of the New Drug

The New Drug is an innovative small molecule chemical drug. In addition to the currently submitted indication, as of the date of this announcement (i.e., 8 January 2026), another indication of the New Drug for the treatment of non-small cell lung cancer (ROS1+) has completed the phase II clinical study in China (excluding Hong Kong, Macau and Taiwan, the same applies below).

As of November 2025, the Group (i.e., the Company and its subsidiaries/units, the same applies below) has invested approximately RMB480 million (unaudited) in total in the research and development of the New Drug at current stage.

According to the latest data from IQVIA CHPA[1], the sales of major drugs for the treatment of non-small cell lung cancer (ALK+) in China in 2024 was approximately RMB 3,367 million.

III. Risk Warning

The New Drug is subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before commercial production. This acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of the pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

8 January 2026

* *For identification purposes only*

[1] Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.